Shares of Bristol Myers Squibb (NYSE: BMY) were down 8.3% as of 11:19 a.m. ET on Thursday. The sell-off came after the big drugmaker announced its first-quarter results before the market opened. Bristol Myers Squibb reported Q1 revenue of $11.9 billion, up 5% year over year. The company posted a loss ...
motleyfoolusx:bmy
Image source: The Motley Fool. Bristol Myers Squibb (NYSE: BMY) Q1 2024 Earnings Call Apr 25, 2024, 8:00 a.m. ET Operator Continue reading
motleyfoolusx:bmy
Many top healthcare stocks provide investors with long-term stability, promising growth prospects, and in some cases even a dividend. Yet, investors don't appear to be sold on the fact that Bristol Myers Squibb (NYSE: BMY) checks off all those boxes. The business faces some concerning challenges in the ...
motleyfoolusx:bmy
Bristol Myers Squibb (NYSE: BMY) reported first quarter 2024 earnings results today. Total revenues increased 5% year-over-year to $11.9 billion. When adjusted for foreign exchange impacts, revenues grew 6%. GAAP net loss attributable to Bristol Myers Squibb was $11.9 billion, or $5.89 per share, compared ...
alphastreetusx:bmy
The healthcare industry can be a good place to invest for the long term. Demand for healthcare is only going to rise as the number of seniors goes up, and general population growth will also mean more of a need for devices, drugs, and healthcare services. Even if you don't have thousands of dollars to ...
motleyfoolusx:isrgusx:bmyusx:nvo
Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its shareholders by constantly raising its payouts -- and if it can do so for long periods -- that's even better. A ...
motleyfoolusx:bmyusx:nvs
Stocks are on a roll. We have been in a bull market for over a year. Major indexes haven't lost their momentum since 2024 started. However, some stocks aren't keeping pace. That's the case with biotech giant Bristol Myers Squibb (NYSE: BMY). The drugmaker has seen its shares drop by 22% over the past ...
motleyfoolusx:bmy
